What is added by this report?
death
Similar SARS-CoV-2 RNA rebound rates were observed in nirmatrelvir/ritonavir and placebo recipients in two randomized, double-blind, clinical trials. Virologic rebound after nirmatrelvir/ritonavir treatment was not associated with COVID-19–related hospitalization or death.